References
- Imbruvica: leading the way with a wave of evidence. [ accessed 2021 Mar 25]. https://imbruvicahcp.com.
- Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787–798. doi:https://doi.org/10.1038/s41375-019-0602-x.
- Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahé B, Herbaux C, Matous JV, Tam CS, et al. Five-year follow-up of ibrutinib plus rituximab vs placebo plus rituximab for Waldenström’s macroglobulinemia: final analysis from the randomized phase 3 iNNOVATETM study. Presented at: ASH Annual Meeting, San Diego, CA; 2020 Dec 5–8.
- Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516. doi:https://doi.org/10.1056/NEJMoa1306220.
- Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243–2250. doi:https://doi.org/10.1182/blood-2017-07-793786.
- Highlights of Prescribing Information. [ accessed 2021 Mar 25]. https://imbruvica.com/files/prescribing-information.pdf.
- Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4;369(1):32–42. doi:https://doi.org/10.1056/NEJMoa1215637.
- Office of clinical pharmacology - FDA, clinical pharmacology and biopharmaceutics review(s). Application Number: 205552Orig2s000; 2014 Jan 28. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205552Orig2s000ClinPharmR.pdf.
- Noy A, de Vos S, Thieblemont C, Martin P, Flowers C, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, et al. Single-agent ibrutinib demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: a multicenter, open-label, phase 2 study. Blood. 2016;128(22):1213. doi:https://doi.org/10.1182/blood.V128.22.1213.1213.
- Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–1440. doi:https://doi.org/10.1056/NEJMoa1501548.
- Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129(18):2581–2584. doi:https://doi.org/10.1182/blood-2016-10-742437.
- Salem J-E, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667–1678. doi:https://doi.org/10.1016/j.jacc.2019.07.056.
- Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, Siegal D. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138–140. doi:https://doi.org/10.1182/blood-2016-05-712828.
- Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18):2199–2205. doi:https://doi.org/10.1182/blood-2016-05-716977.
- Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One. 2019;14(2):e0211228. doi:https://doi.org/10.1371/journal.pone.0211228.
- Tang CPS, McMullen J, Tam C. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leuk Lymphoma. 2018;59:15–64. doi:https://doi.org/10.1080/10428194.2017.1375110.
- Barr PM, Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612–2615. doi:https://doi.org/10.1182/blood-2016-12-737346.
- Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, Iwamoto Y, Wojtkiewicz G, Cetinbas M, Schloss MJ, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation. 2020;142(25):2443–2455. doi:https://doi.org/10.1161/CIRCULATIONAHA.120.049210.
- Ratain MJ, Moslehi JJ, Lichter AS. Ibrutinib’s cardiotoxicity – an opportunity for postmarketing regulation. JAMA Oncol. 2021;7(2):177–178. doi:https://doi.org/10.1001/jamaoncol.2020.5742.
- Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, et al. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014;9(5):1086–1091. doi:https://doi.org/10.1021/cb4008524.
- Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94. doi:https://doi.org/10.1200/JCO.2012.42.7906.
- Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V. Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia. 2016;30:1803–1804. doi:https://doi.org/10.1038/leu.2016.129.
- Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018;132(21):2249–2259. doi:https://doi.org/10.1182/blood-2018-06-860593.
- National Library of Medicine (U.S.). A pilot study on intermittent ibrutinib in patients with advanced-phase chronic lymphocytic leukemia (CLL) (IbruOnOff). Identifier NCT04771507; 2021 Feb.